The Value of Antihypertensive Drugs: A Perspective on Medical Innovation

Presented at: Alliance for Aging Research Briefing

Genia Long
Vice President, Analysis Group, Inc.

February 28th, 2007
“The Value of Antihypertensive Drugs: A Perspective On Medical Innovation”

Study Co-Authors

David M. Cutler  
*Otto Eckstein Professor of Applied Economics, Harvard University*

Ernst R. Berndt  
*Louis B. Seley Professor of Applied Economics, Massachusetts Institute of Technology*

Genia Long, Jimmy Royer, Andree-Anne Fournier and Pierre Cremieux  
*Analysis Group, Inc.*

Alicia Sasser  
*Federal Reserve Bank of Boston*

Study Citation

U.S. age-adjusted death rates from coronary heart disease have fallen by two-thirds since the 1960s

Source: Vital Statistics of the United States, NCHS.
70% of the improvement in life expectancy over this period was due to cardiovascular disease improvement.


- Death from cancer: 0.2
- Death from pneumonia or influenza: 0.3
- Death from external causes: 0.4
- Death in infancy: 1.4
- Death from CVD: 4.9
- Total increase in life expectancy: 7.0

Risk factor progress is mixed: smoking, high cholesterol and hypertension are down, but overweight is up

Cardiovascular Disease Risk Factors in Adults, U.S., 1961-2001

Note: Hypertension is systolic blood pressure $\geq 140$ mm Hg, diastolic blood pressure $\geq 90$ mm Hg, or on antihypertensive medication. High cholesterol is $240+$ mg/dl. Overweight is BMI $25+$ kg/m$^2$.

Source: NHIS for smoking (age 18+) and NHANES for the other risk factors (ages 20–74). As summarized in NHLBI Fact Book, 2005.
Our study questions

- Given current risk factors and behavior, what would blood pressures (BP) have been in the absence of antihypertensive therapy?

- What has been the impact of better controlled blood pressure on:
  - Number of heart attacks and strokes?
  - Deaths from heart attack and stroke?

- How much better could we do if all attained guideline blood pressures?

- What is the cost-benefit of investments in antihypertensive therapy?
  - In terms of life expectancy; excludes benefits from avoided medical costs, productivity losses
The research challenges

“Real world” experience may differ from that in clinical trials:

- Patient compliance rates may be lower
- Overall population may be more heterogeneous and may not experience the same clinical effect as a carefully selected study population
- Other factors affecting rates of disease (e.g., demographics, health habits) may differ or change over time

Many factors may have contributed to improvements observed:

- Other primary and secondary prevention efforts
- Improvement in acute treatment
- Changes in behavior and risk factors
Research approach: holding other factors constant to isolate the impact of better-controlled BP

Estimate regression model for untreated blood pressure

- Estimated from the “drug naïve” 1959-62 NHANES survey to model what BP would be without today’s treatments
- Blood pressure = a function of (age, race, gender, BMI, BMI², diabetes)

Predict untreated BP and compare to observed BP for 1999-00

- Apply model to current risk and demographic factors from the NHANES 1999-2000 survey to estimate what BPs would be in absence of treatment
- Compare to observed, actual blood pressures – the difference is attributed to the impact of antihypertensives

Calculate impact of improvement in BP on risk and number of deaths (2001), heart attack and stroke hospitalizations (2002)

- Using Framingham Heart Study risk equations, population life tables, hospital discharge figures
- Assign a monetary value to reductions in mortality and compare to average expenditures on antihypertensive medication to calculate a cost-benefit ratio
Results: antihypertensive therapy reduced average BP for U.S. men by 10 - 11%

Predicted and Observed Blood Pressure, Men, 1999-2000

Definitions: Optimal: SBP<120, DBP<80; Normal: SBP 120-129, DBP 80-84; High Normal: SBP 130-139, DBP 85-89; Stage I: SBP 140-159, DBP 90-99; Stage II Hypertension: SBP>=160, DBP>= 100

Average BP | Systolic | Diastolic
---|---|---
Predicted | 141.3 | 84.9
Observed | 127.1 | 75.8
% Reduction | 10.0% | 10.7%

Analysis Group
Results: antihypertensive therapy reduced average BP for U.S. women by 10 - 13%
Research results: Impact on U.S. health outcomes

- 86,000 excess premature deaths from CVD avoided (2001)
- 572,000 hospital discharges for stroke avoided (2002)
- 261,000 hospital discharges for heart attack avoided (2002)

Predicted and Observed Deaths, 2001, and Hospital Discharges for Stroke and MI, 2002, Men and Women

- Deaths from Major Cardiovascular Disease (2001)
- Hospital Discharges for Stroke (2002)
- Hospital Discharges for Myocardial Infarction (2002)

Legend:
- Observed
- Predicted Without Antihypertensives
- Predicted if All at Guidelines
How significant are these estimated reductions relative to some other causes of mortality?

- Would have approached all deaths from accidents (98,000, the 5th largest cause of death in 1999-00)
- Would have exceeded all deaths from influenza and pneumonia (64,000, the 7th largest cause of death)
- Roughly equivalent to the number of people who are estimated to die of medical errors annually
- Would have exceeded all deaths from motor vehicle accidents (42,000 in 2001)
There are still significant opportunities for improvement

If all untreated patients with Stage I or II hypertension had been treated and all achieved normal blood pressures

- An additional **89,000 fewer excess premature deaths from major cardiovascular disease** in the U.S. in 2001
- An estimated **278,000 fewer US hospital discharges for stroke** and **142,000 fewer discharges for myocardial infarctions** in 2002 than actually occurred

➢ So far, we have achieved *approximately half* of the potential health gains
Cost benefit: we calculate an approximate benefit-to-cost ratio of 10:1 for men and 6:1 for women

- Assume each year of additional life in good health is worth $90,000 a year
- Compare discounted lifetime costs for antihypertensive drugs with discounted benefits of additional years of life
- Including benefits other than extended life would increase calculated net benefits further:
  - Reduced hospitalizations for stroke and MI
  - Impact of antihypertensive drugs on quality of life, work productivity
Implications

With an aging population, the total burden of cardiovascular disease will increase:

- As one of the most significant modifiable health risks, and in light of the attractive cost-benefit ratio, hypertension control should be prioritized for outreach, education, and compliance efforts.

- Under-utilization of effective, cost-efficient therapies continues to be a major public health challenge.
Caveats

- Residual analysis – factors not controlled for could affect BP trends
  - Sensitivity analyses on sodium intake and exercise conducted; neither increased explanatory power of the model significantly

- Due to potential competing risks, estimates represent reductions in premature deaths due to cardiovascular disease
  - Reductions in total mortality from all causes in a given year may be lower